News

• The European Commission has approved the first IPCEI in health, with up to €1 billion in public funding and €5.9 billion expected in private investments.
• REIG JOFRE will participate in the EMINTECH project of the Med4Cure consortium, bringing its expertise and knowledge in the development of advanced pharmaceutical technologies to new personalized therapies and unresolved infections.

REIG JOFRE, (BME:RJF), a pharmaceutical company listed on the continuous market of the Spanish stock exchange, which researches, develops, manufactures, and commercializes essential pharmaceutical products for people’s health, announces the European Commission’s approval, in accordance with EU state aid rules, of the first Important Project of Common European Interest (IPCEI). This project is designed to support research, innovation, and the initial deployment in the sector of medical products and innovative pharmaceutical production processes.

The European Commission approves up to €1 billion in state aid from six Member States: Belgium, Slovakia, Spain, France, Hungary, and Italy, with the expectation of unlocking an additional €5.9 billion in private investments.

REIG JOFRE has been selected to participate as an Associated Partner in the Consortium. Med4Cure is a major project that includes 14 scientific projects to be developed by 13 companies as Direct Partners and 11 as Associated Partners.

The project in which REIG JOFRE will participate is called EMINTECH. Its objective is to develop new technological strategies to combat unresolved infections, focusing on the following areas: advanced therapies (cell therapy), new treatments based on immunotherapies, bacteriophages, and therapeutic vaccines for patients with antibiotic resistance.

REIG JOFRE plans to contribute its extensive experience in pharmaceutical development and new therapy technologies, facilitating their evolution from research to clinical trials.